Thermodynamic and structural characterization of halogen bonding in protein-ligand interactions: a case study of PDE5 and its inhibitors.

The significance of halogen bonding in protein-ligand interactions has been recognized recently. We present here the first comprehensive thermodynamic and structural characterization of halogen bonding in PDE5-inhibitor interactions. ITC studies reveal that binding strength of the halogen bonding between chlorine, bromine, and iodine of inhibitor and the protein is -1.57, -3.09, and -5.59 kJ/mol, respectively. The halogens interact with the designed residue Y612 and an unexpected buried water molecule.

[1]  Hualiang Jiang,et al.  Design, synthesis, and pharmacological evaluation of monocyclic pyrimidinones as novel inhibitors of PDE5. , 2012, Journal of medicinal chemistry.

[2]  Hualiang Jiang,et al.  Exploration of the 5-bromopyrimidin-4(3H)-ones as potent inhibitors of PDE5. , 2013, Bioorganic & medicinal chemistry letters.

[3]  M. Chudziński,et al.  Halogen bonding in solution: thermodynamics and applications. , 2013, Chemical Society reviews.

[4]  Markus O. Zimmermann,et al.  Targeting Histidine Side Chains in Molecular Design through Nitrogen-Halogen Bonds , 2013, J. Chem. Inf. Model..

[5]  M. Giorgi,et al.  Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain. , 2001, Biochimica et biophysica acta.

[6]  M. Bunnage,et al.  The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokinetics. , 2012, Bioorganic & medicinal chemistry.

[7]  Weiliang Zhu,et al.  Halogen Bond: Its Role beyond Drug-Target Binding Affinity for Drug Discovery and Development , 2014, J. Chem. Inf. Model..

[8]  François Diederich,et al.  Systematic investigation of halogen bonding in protein-ligand interactions. , 2011, Angewandte Chemie.

[9]  Markus O. Zimmermann,et al.  Halogen-Enriched Fragment Libraries as Leads for Drug Rescue of Mutant p53 , 2012, Journal of the American Chemical Society.

[10]  K. Ziegelbauer,et al.  PDE5 inhibitors beyond erectile dysfunction , 2007, International Journal of Impotence Research.

[11]  M. Garneau,et al.  Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335). , 2010, Journal of medicinal chemistry.

[12]  Weiliang Zhu,et al.  Halogen bonding--a novel interaction for rational drug design? , 2009, Journal of medicinal chemistry.

[13]  J M Thornton,et al.  LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. , 1995, Protein engineering.

[14]  Eric Westhof,et al.  Halogen bonds in biological molecules. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Weiliang Zhu,et al.  Halogen bonding for rational drug design and new drug discovery , 2012, Expert opinion on drug discovery.

[16]  A. Abadi,et al.  Synthesis and molecular modeling of novel tetrahydro-β-carboline derivatives with phosphodiesterase 5 inhibitory and anticancer properties. , 2011, Journal of medicinal chemistry.

[17]  P. Robach,et al.  Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertension. , 2005, American journal of respiratory and critical care medicine.

[18]  R. Kloner,et al.  Drug Interactions With Phosphodiesterase-5 Inhibitors Used for the Treatment of Erectile Dysfunction or Pulmonary Hypertension , 2010, Circulation.

[19]  Hisayoshi Kobayashi,et al.  Diastereomers of dibromo-7-epi-10-deacetylcephalomannine: crowded and cytotoxic taxanes exhibit halogen bonds. , 2006, Journal of medicinal chemistry.

[20]  Martin Stahl,et al.  Fluorine in Medicinal Chemistry , 2004, Chembiochem : a European journal of chemical biology.

[21]  Connie M. Gryniewicz-Ruzicka,et al.  Rapid-screening detection of acetildenafils, sildenafils and avanafil by ion mobility spectrometry. , 2013, Journal of pharmaceutical and biomedical analysis.

[22]  G. Muirhead,et al.  Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. , 1996, International journal of impotence research.

[23]  Marcelo Zaldini Hernandes,et al.  Halogen atoms in the modern medicinal chemistry: hints for the drug design. , 2010, Current drug targets.

[24]  D. Kouvelas,et al.  PDE5 inhibitors: in vitro and in vivo pharmacological profile. , 2009, Current pharmaceutical design.

[25]  Weiliang Zhu,et al.  Utilization of halogen bond in lead optimization: a case study of rational design of potent phosphodiesterase type 5 (PDE5) inhibitors. , 2011, Journal of medicinal chemistry.

[26]  Markus O. Zimmermann,et al.  Using halogen bonds to address the protein backbone: a systematic evaluation , 2012, Journal of Computer-Aided Molecular Design.

[27]  Barbara Kirchner,et al.  Addressing Methionine in Molecular Design through Directed Sulfur-Halogen Bonds. , 2011, Journal of chemical theory and computation.

[28]  Pierangelo Metrangolo,et al.  Halogen bonding in halocarbon-protein complexes: a structural survey. , 2011, Chemical Society reviews.

[29]  P Shing Ho,et al.  Enthalpy-entropy compensation in biomolecular halogen bonds measured in DNA junctions. , 2013, Biochemistry.

[30]  Nobuo Shimma,et al.  Halogen Bonding at the Active Sites of Human Cathepsin L and MEK1 Kinase: Efficient Interactions in Different Environments , 2011, ChemMedChem.

[31]  A. Joerger,et al.  Principles and applications of halogen bonding in medicinal chemistry and chemical biology. , 2013, Journal of medicinal chemistry.

[32]  Jóhannes Reynisson,et al.  Known drug space as a metric in exploring the boundaries of drug-like chemical space. , 2009, European journal of medicinal chemistry.

[33]  O. Hucke,et al.  Combined X-ray, NMR, and Kinetic Analyses Reveal Uncommon Binding Characteristics of the Hepatitis C Virus NS3-NS4A Protease Inhibitor BI 201335* , 2011, The Journal of Biological Chemistry.

[34]  P Voth Regier Andrea and Ho Shing,et al.  The role of halogen bonding in inhibitor recognition and binding by protein kinases. , 2007 .